Streetwise Reports' Article Archives — Current Month (19)
Analyst Has Confidence in Biotech's Path (06/26/2025)
Vertex Pharmaceuticals Inc.'s (VRTX:NASDAQ) updated data is "a strong positive read-through for Sernova and help de-risk the broader field of cell-based therapies in T1D," according to an H.C. Wainwright & Co. research note.
Isotope Co. Discovers Uranium-Helium Breakthrough Potential (06/24/2025)
ASP Isotopes Inc. (ASPI:NASDAQ) is seeing at least two major transformative developments this month. Read why one analyst sees these events as positive.
Analyst Shares Thoughts After Microdisplay Co.'s Demo Day (06/23/2025)
Kopin Corp.'s (KOPN:NASDAQ) display and optical technologies as well as its products are impressive, noted a Lake Street Capital Markets report.
Biotech Boasts Compelling Pipeline (06/23/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) is exploring financing options with some potential sources of capital, noted a Research Capital Corp. report.
Sirens of High Finance (06/23/2025)
Michael Ballanger of GGM Advisory Inc. shares his take on the current state of the market and reviews one copper stock he has been betting on for a while.
California Biotech's Trial Shows Encouraging Results (06/20/2025)
Kura Oncology Inc.'s (KURA:NASDAQ) KOMET-007 trial results, supporting ziftomenib's benefit-risk profile for first-line acute myeloid leukemia, were encouraging, according to an H.C. Wainwright & Co. research note.
Orogen: End of Another Chapter Draws Near (06/16/2025)
Global Analyst Adrian Day discusses developments at some companies on his list, including Orogen Royalties Inc. (OGN:TSXV; OGNRF:OTCQX) and Franco-Nevada Corp. (FNV:TSX; FNV:NYSE).
AI-Powered Medical Education Suite Cuts Costs, whilst Enhancing Clinical Skills Training for Future Doctors (06/16/2025)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launched its enhanced medical education suite in Minnesota, showing strong reliability and providing schools with up to 40% cost savings. Read on to find out how AI-simulated patients are reshaping medical education and enhancing clinical skills at scale.
Q1/25 Financials of Cancer Drug Developer Released (06/12/2025)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report.
Biotech Firm Unveils Diabetes Breakthrough in Canada (06/10/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes.
New RA Drug Shown to Work, Be Safe (06/10/2025)
"Efficacy at six months represented a 'best case' scenario, in our view," and "safety was very favorable," noted a Wedbush report.
Analyst Likes Co. Developing Immuno-oncology Drugs (06/10/2025)
There are multiple reasons to be bullish on this undervalued stock with significant potential upside, noted an H.C. Wainwright & Co. report.
Co.'s New Cancer Drug Shows Promise (06/09/2025)
Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report.
Biotech Co. Reaches MS Clinical Program Milestones (06/09/2025)
These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report.
Phase 2b Trial Data on Treatment for Inflammation Due Soon (06/09/2025)
These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report.
Canadian Biotech Advances High-Impact DDR Programs (06/06/2025)
Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy.
Healthcare Firm Uncovers AI Healthcare Growth Opportunity (06/06/2025)
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock.
Biotech Company Unlocks Gene Therapy Breakthrough in Canada (06/06/2025)
PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.
Data Readout Positive from Trial of New Schizophrenia Drug (06/04/2025)
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report.
More Archives
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
